Oncolytic virus, which can infect and lyse tumor cells, has been identified to reverse the primary resistance to PD-1 blockade therapy through increasing intratumoral infiltration by CD8+ T cells and elevating PD-L1 expression (191, 192). Here, PDCD1 is linked to neoplasm.